Press Releases

 
Press Releases
  Date Title and Summary View
Apr 2, 2014
Santa Monica, CA – April 2, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Arie Belldegrun, M.D., FACS, as President and Chief Executive Officer.  Dr. Belldegrun, who ...
Mar 31, 2014
Los Angeles, CA – March 31, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation f...
Jan 17, 2014
LOS ANGELES, Jan. 17, 2014 -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Rizwana F. Sproule, Ph.D., to...
Jan 9, 2014
New York, Jan. 9, 2014 -- NeoStem, Inc. (NASDAQ:NBS) and its subsidiary, Progenitor Cell Therapy, LLC (“PCT”), announced today the execution of a Services Agreement with Kite Pharma, Inc., under which PCT will provide cell therapy process development and manufacturing services for Kite Pharma’s lead engineered Autologous T...
Jan 8, 2014
Los Angeles, CA – January 8, 2014 – Kite Pharma Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Cynthia M. Butitta to the newly created position of Executive Vice President and Chief Financial Offic...
Dec 7, 2013
At the 2013 American Society of Hematology meeting in Dec. 2013, James Kochenderfer, M.D., investigator in the Experimental Transplantation and Immunology Branch, NCI, presented findings from two clinical trials evaluating the use of genetically modified immune system T cells as cancer therapy.  These studies were performed in close co...
Dec 7, 2013
Los Angeles, CA – December 7, 2013 – Kite Pharma, Inc. (Kite), today announced that Dr. Arie Belldegrun, Executive Chairman and Founder of Kite Pharma, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014, at 1:30 p.m. Pacific Time.  The conference will be held at the We...
Dec 7, 2013
LOS ANGELES, CA (December 7, 2013) -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on engineered autologous T cell therapy (eACT) products for cancer, today announced positive clinical data demonstrating that Kite’s most advanced product candidate can produce robust and ...
Aug 8, 2013
Los Angeles, CA - August 8, 2013 - Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced the appointment of three leading experts in the areas of immunotherapy, chimeric antigen receptor (CAR) te...
May 30, 2013
Los Angeles, CA (May 30, 2013) -- Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced the appointment of Keith Nolop, M.D. as Chief Medical Officer. Dr. Nolop, who brings to Kite over 20 years of successful drug development experien...
Page: FirstPrevious ...
18
NextLast
= add release to Briefcase